pharmaphorum January 13, 2025
Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma M&A announcement today.
The $132-per-share agreement comes a few months after Intra-Cellular reported phase 3 results with its only commercial product Caplyta (lumateperone) that could dramatically expand its market. Shares in Intra-Cellular had rocketed by more than a third to more than $128 at the time of writing.
Caplyta is already approved by the FDA to treat schizophrenia and bipolar depression as monotherapy and in combination with lithium or valproate, but has also shown efficacy in major depressive disorder (MDD), a larger indication that RBC Capital Markets analysts think could drive sales above $3 billion a year.
To...
Today's Sponsors
Today's Sponsor